118 related articles for article (PubMed ID: 16481522)
1. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.
Rolain JM; Lambert F; Raoult D
Ann N Y Acad Sci; 2005 Dec; 1063():252-6. PubMed ID: 16481522
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.
Gikas A; Spyridaki I; Scoulica E; Psaroulaki A; Tselentis Y
Antimicrob Agents Chemother; 2001 Nov; 45(11):3276-8. PubMed ID: 11600400
[TBL] [Abstract][Full Text] [Related]
3. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.
Rolain JM; Boulos A; Mallet MN; Raoult D
Antimicrob Agents Chemother; 2005 Jul; 49(7):2673-6. PubMed ID: 15980335
[TBL] [Abstract][Full Text] [Related]
4. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.
Spyridaki I; Psaroulaki A; Vranakis I; Tselentis Y; Gikas A
Antimicrob Agents Chemother; 2009 Jun; 53(6):2690-2. PubMed ID: 19332671
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rifapentine and other rifamycins against
Miller HK; Kersh GJ
Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598
[TBL] [Abstract][Full Text] [Related]
6. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.
Rolain JM; Maurin M; Raoult D
Antimicrob Agents Chemother; 2001 Jan; 45(1):301-2. PubMed ID: 11120982
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine susceptibility determination of Coxiella burnetii in human embryonic lung (HEL) fibroblast cells.
Angelakis E; Khalil JB; Le Bideau M; Perreal C; La Scola B; Raoult D
Int J Antimicrob Agents; 2017 Jul; 50(1):106-109. PubMed ID: 28478211
[TBL] [Abstract][Full Text] [Related]
8. Activities of telithromycin, erythromycin, fluoroquinolones, and doxycycline against Campylobacter strains isolated from Finnish subjects.
Schönberg-Norio D; Hänninen ML; Katila ML; Kaukoranta SS; Koskela M; Eerola E; Uksila J; Pajarre S; Rautelin H
Antimicrob Agents Chemother; 2006 Mar; 50(3):1086-8. PubMed ID: 16495275
[TBL] [Abstract][Full Text] [Related]
9. Measurement of the antibiotic susceptibility of Coxiella burnetii using real time PCR.
Boulos A; Rolain JM; Maurin M; Raoult D
Int J Antimicrob Agents; 2004 Feb; 23(2):169-74. PubMed ID: 15013043
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.
Rolain JM; Maurin M; Bryskier A; Raoult D
Antimicrob Agents Chemother; 2000 May; 44(5):1391-3. PubMed ID: 10770788
[TBL] [Abstract][Full Text] [Related]
11. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
Gikas A; Spyridaki I; Psaroulaki A; Kofterithis D; Tselentis Y
Antimicrob Agents Chemother; 1998 Oct; 42(10):2747-8. PubMed ID: 9756789
[TBL] [Abstract][Full Text] [Related]
13. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS
Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii.
Andoh M; Naganawa T; Yamaguchi T; Fukushi H; Hirai K
Microbiol Immunol; 2004; 48(9):661-4. PubMed ID: 15383702
[TBL] [Abstract][Full Text] [Related]
15. [Drug activity against Coxiella burnetii, a pathogen of Q fever].
Tokarevich NK
Antibiot Khimioter; 2007; 52(1-2):46-56. PubMed ID: 18461810
[No Abstract] [Full Text] [Related]
16. Genome sequence of Coxiella burnetii 109, a doxycycline-resistant clinical isolate.
Rouli L; Rolain JM; El Filali A; Robert C; Raoult D
J Bacteriol; 2012 Dec; 194(24):6939. PubMed ID: 23209205
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones.
Lever MS; Bewley KR; Dowsett B; Lloyd G
Int J Antimicrob Agents; 2004 Aug; 24(2):194-6. PubMed ID: 15288324
[No Abstract] [Full Text] [Related]
18. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
Jalava J; Kataja J; Seppälä H; Huovinen P
Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
[TBL] [Abstract][Full Text] [Related]
19. Use of axenic media to determine antibiotic efficacy against coxiella burnetii.
Clay KA; Hartley MG; Russell P; Norville IH
Int J Antimicrob Agents; 2018 May; 51(5):806-808. PubMed ID: 28802854
[TBL] [Abstract][Full Text] [Related]
20. Use of macrolides for Q fever.
Raoult D
Antimicrob Agents Chemother; 2003 Jan; 47(1):446. PubMed ID: 12499237
[No Abstract] [Full Text] [Related]
[Next] [New Search]
